Navigation Links
Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
Date:4/28/2011

BETHLEHEM, Pa., April 28, 2011 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Celanese EVA Performance Polymers, a leading supplier of ethylene vinyl acetate (EVA) into pharmaceutical applications, are working together to streamline the development of drug-eluting devices.  Building on years of collaboration, Particle Sciences and Celanese EVA Performance Polymers are working to provide Particle Sciences with preferred access to VitalDose™ EVA polymer in early stage projects.  

According to Andrew Loxley, Particle Sciences' Director of New Technologies, "With combination products, devices that deliver drugs, there are multiple parties involved including the innovator, the API supplier, the development group and the polymer supplier.  All parties want to ensure a quality product.  Particle Sciences and Celanese EVA Performance Polymers have been collaborating for a number of years and, because of that relationship, are now in a position to expedite the process."

With this collaboration, there is a highly streamlined process by which Particle Sciences obtains access to use Celanese EVA polymers in early development efforts.  Jamie Beggs, Marketing Development Manager, Celanese EVA Performance Polymers, states, "We are committed to becoming the premier EVA excipient producer and have been providing EVA technology for medical applications for years.  Our VitalDose brand delivers the reliable performance required for pharma applications combined with in-depth technical expertise and comprehensive regulatory knowledge.  This partnership is a testament to the degree to which we have developed confidence in Particle Sciences' capabilities and their focus on quality.  With their capabilities in prototyping, characterization, experience with controlled and highly potent substances and cGMP facilities, they have consistently delivered innovation to our customers."

Robert Lee, Vice President Pharmaceutical Development at Particle Sciences adds, "Combination products have unique development challenges.  For each project, it's important that we start with an open mind as to polymer choice and device architecture.  For our EVA needs, we are extremely pleased to be aligned with Celanese EVA Performance Polymers, the group we believe to be most appropriately addressing this market."

Particle Sciences Inc. is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery.  Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Celanese EVA Performance Polymers Inc. is a North American leader in developing products and application technology to improve performance, create value and drive innovation in a broad range of industrial and consumer end-use applications including flexible packaging, thermal lamination film, hot melt adhesive, USP class VI medical products and photovoltaic cells.  The business has manufacturing facilities in Edmonton, Canada, and is supported by expert technical service.  More information about Celanese EVA Performance Polymers Inc. is available at www.celanese-EVA.com.

Contact: Maureen Cochran
mcochran@particlesciences.com
610-861-4701


'/>"/>
SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
2. IBA Particle Therapys $20,000 Grant Helps Non-Profit Ease Costs for Children Traveling to Receive Proton Therapy
3. Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens
4. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
5. Particle Sciences and SoluBest Enter into Technology Agreement
6. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
7. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
8. Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
9. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
10. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
11. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with ... 2016 financial results press release, you are invited to ... live over the internet on Tuesday, March 14, 2017 ... A live audio webcast of the presentation ... www.durect.com and clicking "Investor Relations."  If you are ...
(Date:2/24/2017)... YORK , Feb. 24, 2017 ... Monteverde & Associates PC , a boutique securities firm ... New York City , announces that a class ... Massachusetts  against Inotek Pharmaceuticals Corporation ... of the Company,s securities between July 23, 2015 and December ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... Smart Machine Age is here, and it’s disrupting everything. Not only could it drive ... United States may be taken over by technology in the next five to fifteen ... colleagues is drawing to a close. Success will belong to those who can quiet ...
(Date:2/24/2017)... ... 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ... his paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles ... , Schanssema, initially unsure of the career path he wanted to take, found fulfillment ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating ... Me Beyond What You See” body image mannequin art competition. Selected from 15 submissions ... and the winner revealed at the 31st annual iaedp Symposium, March 22 – 26 ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... qualifying into the Senior International Elite division on February 12th. Ms. Esparza ... divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida is ...
(Date:2/23/2017)... ... 23, 2017 , ... The 89th Academy Awards will be celebrated this weekend, ... Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” ... is the Center for American Progress (CAP), for its report, Lessons From State Performance ...
Breaking Medicine News(10 mins):